

6. (Amended) The use according to claim 1 wherein MMDX is administered as an infusion of from about 15 minutes to about 30 minutes every 4 weeks.

7. (Amended) The use according to claim 1 wherein MMDX is administered as a 5-10 minute bolus every 8 weeks.

8. (Amended) The use according to claim 1 wherein MMDX is administered with an agent which remains selectively in a liver tumor after its injection through the hepatic artery.

9. (Amended) The use according to claim 8 wherein the agent is iodized oil.

10. (Amended) The use according to claim 1 wherein MMDX is administered in a dose ranging from about 100 mcg/m² to about 1000 mcg/m².

11. (Amended) The use according to claim 10 wherein MMDX is administered in a dose ranging form about 100 mcg/m² to about 800 mcg/m².

12. (Amended) The use according to claim 11 wherein the dose is 200 mcg/m².

15. (Amended) The use of a pharmaceutical composition according to claim 13 for the treatment of a liver tumor.

16. (Amended) The use of a pharmaceutical composition which comprises as an active principle MMDX and a pharmaceutically acceptable agent which remains selectively in a liver tumor after its injection through the hepatic artery, for the preparation of a medicament formulated for intrahepatic administration in the treatment of a human liver tumor.

17. (Amended) The use according to claim 16 wherein the agent is iodized oil.